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Abstract
Background: The imbalance between extracellular matrix components is a consequence of MMPs activity. Increased expression of matrix metalloproteinases 
(MMPs), in particular type 2 and 9, has been identified in varicose veins. MMP-2 and -9 have acute venodilatory effect in addition to their known effects 
on the extracellular matrix. The data suggest that protracted increases in venous pressure and wall tension increase MMPs expression, which in turn 
reduce venous contraction and lead to progressive venous dilation. Increases in magnitude and duration of wall tension are associated with reduced 
contraction and overexpression of MMP-2 and -9. MMP-2 and -9 promote inferior vena cava relaxation. MMP-2 did not inhibit venous contraction 
during membrane depolarization by high KCl, suggesting that MMP-2 induced relaxation likely involves hyperpolarization and activation of a K+ 
channel. MMPs cause hyperpolarization of the smooth muscle cells of the vein wall, leading to prolonged opening of Ca2+-dependent K+ channel (BKCa).
Conclusions: MMP-2 causes significant inhibition of Phenylephrine and Angiotensin II-induced IVC contraction likely through a post-receptor 
mechanism involving activation of plasmalemmal K+ channels, membrane hyperpolarization, and inhibition of Ca2+influx. MMP-2 induced inhibition of 
the Ca2+ entry mechanism of venous smooth muscle contraction may play a role in the venous dilation associated with varicose vein formation. Studying 
the mechanisms of action of MMPs is an important step in the development of new treatment methods of varicose veins, such as synthetic inhibitors 
of matrix metalloproteinases.
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Introduction
Throughout time phlebology has been the subject of much 
research and workings, and today the theme is more actual 
than ever due to numerous progresses in research, to the de-
velopment of diagnosis and treatment technologies, and the 
people’s medico-sanitary conscience evolution [1]. Varicose 
veins affect up to 25 percent of women and 15 percent of men. 
By the age of 50, nearly 40 percent of women and 20 percent 
of men have significant leg vein problems [2].
Studying this theme is too important because currently 
there are a number of treatments: sclerotherapy, laser therapy 
and surgical treatment, all accompanied by administering of 
phlebotonics and wearing bandages compression, but none 
of them resolves the problem, and recurrent varicose veins 
is an evidence of that. Despite medical and socio-economic 
consequences of varicose veins, the pathophysiological me-
chanisms involved are not fully understood. Although there 
were identified risk factors for varicose veins, such as female 
gender, pregnancy, obesity, aging, family history, the mole-
cular mechanisms underlying pathogenicity and progressive 
varicose veins remain unclear. The tendency of most studies 
is hereditary component orientation and the genetic patho-
genesis [1,3,4].
For example, the genetic mutations in iron metabolism 
genes may play a role in varicose veins (VVs). Prolonged 
venous reflux is associated with iron overload and dermal 
hemosiderin deposition that is directly correlated with clinical 
symptoms of chronic venous insufficiency (CVI) including 
skin changes and lipodermatosclerosis. Iron deposition may 
induce the formation of free radicals which can cause further 
tissue injury, and progression to advanced forms of CVI and 
leg ulcers. Also, Factor XIII is a cross-linking protein that plays 
a key role in ulcer healing. Mutations in hemochromatosis 
C282Y (HFE) gene and Factor XIII V34L gene variants have 
been identified in patients with chronic venous disease (CVD) 
and have been associated with increased risk of severe forms 
of CVI, skin changes and the size of venous ulcers. Some 
clinical conditions support a genetic component of VVs. 
Patients with Klippel-Trenaunay Syndrome have congenital 
venous anomalies in the form of atresia, agenesis of the deep 
venous system, valve insufficiency, venous aneurysms, and 
embryonic veins [4].
The primary cause of varicose vein formation is not clear; 
however, both vein valve dysfunction and hydrostatic venous 
pressure appear to play a critical role in the initiation and 
progression of the disease. Although valve-reflux may precede 
vein-dilatation,there is a significant body of evidence suppor-
ting the view that vein dilation can precede venous reflux, and 
that valvular dysfunction may be an epiphenomenon of vein 
wall dilation. Clinical studies have demonstrated that venous 
insufficiency can occur in varicosities without axial reflux of 
the superficial, deep or perforated veins, and that an imbalance 
in extracellular matrix proteins may cause connective tissue 
changes prior to valvular insufficiency [5].
Recent studies suggest that the balance between vascular 
proliferation, extracellular matrix deposition and degradation 
can be disturbed leading to loss of mechanical strength of the 
wall, venous dilatation and elongation. Fundamental changes 
in varicose dilatation involving cross linking and structural 
changes in the vein wall, inclusive fragmentation and disor-
ganization of elastin smooth muscle [5].
Advanced stages of varicose veins are characterized by 
degeneration of the extracellular matrix, the endothelium 
and of smooth muscle cells of the vein wall. Histologically is 
modified extracellular matrix that shows the fragmentation of 
elastic blades, loss of circular and longitudinal fiber of smooth 
muscle and deterioration of endothelium [6,7]. Venturi [8, 
9] and his co-workers have shown a decrease in desmosine,
isodesomsinei and elastin collagen ratio in varicose veins 
compared to normal veins. C. Michiels [9] has shown that 
hypoxia induced leukocyte activation and generation of free 
radicals, activation of proteases, and therefore, the degradation 
of the extracellular matrix. Additionally, they have demonstra-
ted that hypoxia activates endothelial cells to secrete growth 
factors and stimulate smooth muscle cell (SMC) proliferation 
and synthesis of extracellular matrix. These studies suggest 
that the disturbance in the synthesis and degradation of struc-
tural elements appear in the segments of varicose veins. The 
degradation of extracellular matrix triggeres the leukocyte 
infiltration and activates the inflammation which damages the 
vein wall. Vascular wall remodeling depends on the activity 
of macrophages, SMC, endothelial cells and fibroblasts. The 
extracellular matrix is made of SMC and fibroblasts and is 
degraded by enzymes secreted by the macrophages, such as 
matrix metalloproteinases (MMPs). The change in collagen-
elastin ratio, which is observed in varicose veins, indicates 
an imbalance in the connective tissue matrix. Also, there are 
observed significant variations in the ratio of collagen type I 
and type II and increasing the activity of MMP, in particular 
2 to 9 [4, 7]. All this has determined the shift towards the 
new direction of study. The research is based on the treatemet 
methods discovery which is focused physiopathologically at 
cellular and molecular level. The article is based in particular 
on the work of West Roxbury vascular surgeon and resear-
cher Joseph D. Raffetto [3,5,7], professor at the University of 
Massachusetts.
Recent studies are based on the research of MMPs in the 
development and progression of varicose veins. MMPs were 
described initially by Jerome Grossand and Charles Lapiere 
[10, 11], who observed enzymatic activity (collagen triple 
helixdegradation) during tadpole tail metamorphosis (by 
placing a tadpole tail in a collagen matrix plate). Therefore, the 
enzyme was named interstitial collagenase (MMP-1). Later, 
it was purified from human skin [10]. Since then, the MMP 
family has grown to include at least 28 members in vertebrates, 
23 in humans, and 14 in blood vessels [4].
MMPs are also called matrixins, they are multidomain 
zinc metalloproteinases that degrade various components of 
extracellular matrix (ECM) and belong to the larger super-
family of proteases called metzincins, which also includes 
adamalysins, serralysins, and astacins. Sequence homology 
with the catalytic domain of MMP-1 (collagenase 1) is a com-
mon feature of all members of the MMP family. To classify 
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MMPs there have been employed several methods. MMPs are 
classified as the matrixin subfamily of zinc metalloprotease 
family. The most common methods of classification MMPs 
are based on organization domain and substrate preference 
into collagenases, gelatinases, stromelysins, matrilysins, 
membrane-type (MT)-MMPs and others [4]. From the evo-
lutionary point of view MMPs have been classified depending 
on their primary sequence into 6 subgroups (A–F): subgroup 
A (MMP-19, -26, -28), B (MMP -11, -21, -23), C (MMP-17, 
-25), D (MMP-1, -3, -8, -10, -12, -13, -27), E (MMP-14, -15, 
-16, -24), and F (MMP-2, -7, -9, -20) [13]. Thus MMP 1 is 
interstitial collagenase and its substrate is fibrillar collagen, 
MMP 2 and 9 are the gelatinases which acts on collagen type 
IV, V, collagen degraded and elastin, and MMP3 is stromelysin 
and has the substrate proteoglycans, fibronectin, laminin, pro 
MMP-1 9. Other subgroups include: matrilysin, enamelysin 
and metalloelastase macrophagal [13].
Matrix metalloproteinases are excreted by connective 
tissue and a variety of pro-inflammatory cells including 
fibroblasts, osteoblasts, endothelial cells, macrophages, neu-
trophils, and lymphocytes. These enzymes are expressed as 
zymogens, which are subsequently processed by other prote-
olytic enzymes (such as serine proteases, furin, plasmin, and 
others) to generate the active forms. Typically MMPs consist 
of a propeptide of about 80 amino acids, a catalytic metallo-
proteinase domain of about 170 amino acids, a linker peptide 
(hinge region) of variable lengths and a hemopexin domain 
of about 200 amino acids. The catalytic domain contains 
the Zn2+ binding motif HEXXHXXGXXH and a conserved 
methionine [11].
Most of the matrix metalloproteinases consist of four 
distinct domains, which are N-terminal pro-domain, catalytic 
domain, hinge region, and C-terminal hemopexin-like doma-
in. This may be responsible for the macromolecular substrate 
recognition as well as for interaction with tissue inhibitors 
of metalloproteinases (TIMPs). The membrane-type MMPs 
contain an additional transmembrane domain that anchors 
them in the cell surface [14]. 
MMPs are synthesized as pre-proenzymes. The signal 
peptide is removed during translation and proMMPs are gene-
rated. Activation of these zymogens is therefore an important 
regulatory step of MMP activity.
Thirteen MMPs are secreted from the cell as proMMPs. 
The presence of a proteinase susceptible “bait” region in the 
propeptide allows tissue and plasma proteinases or opportu-
nistic bacterial proteinases to activate proMMPs. Cleavage 
of the bait region removes only a part of the propeptide and 
complete removal of the propeptide is often conducted in 
trans by the action of the MMP intermediate or by other 
active MMPs [15].
MMPs degrade different components of ECM including 
collagen, casein and laminin. MMPs also modulate many 
bioactive molecules at the cell surface, and may regulate the 
cellular environment via interaction with G-protein coupled 
receptors. MMPs may play a role in cell proliferation, migra-
tion (adhesion/dispersion), differentiation and apoptosis, 
as well as physiological processes such as immune function, 
tissue healing, and angiogenesis. Matrixins participate in 
many normal biological processes (embryonic development, 
blastocyst implantation, organ morphogenesis, nerve growth, 
ovulation, cervical dilatation, postpartum uterine involution, 
endometrial cycling, hair follicle cycling, bone remodeling, 
wound healing, angiogenesis, apoptosis, etc.) and pathological 
processes (arthritis, cancer, cardiovascular disease, nephritis, 
neurological disease, breakdown of blood brain barrier, peri-
odontal disease, skin ulceration, gastric ulcer, corneal ulcera-
tion, liver fibrosis, emphysema, fibrotic lung disease, etc.). Al-
though the main function of matrixins is the removal of ECM 
during tissue resorption and progression of many diseases, it 
is notable that MMPs also alter biological functions of ECM 
macromolecules by specific proteolysis. For example, MMP-2 
released by growth cones promotes neurite outgrowth by inac-
tivating neurite-inhibitory chondroitin sulfate proteoglycans, 
thereby unmasking the neurite-promoting activity of laminin 
[11]. Among lung injuries, MMPs have been implicated in 
acute respiratory distress syndrome and chronic obstructive 
pulmonary disease, which encompasses both emphysema 
and chronic bronchitis. There has been considerable interest 
in the role that MMPs play on the progression of tumours to 
metastatic neoplasms. In neurodegenerative diseases, such 
as Alzheimer’s disease and Parkinson’s disease, MMPs have 
been shown to play an important and complex role. MMPs 
have been shown to increase blood-brain barrier permeability 
that can cause oedema, haemorrhage and cell death and it is 
thought to play a role in white matter damage [16].
MMPs are regulated at multiple levels including tran-
scription, secretion, and activation of the zymogen forms, 
extracellular inhibition and internalization by endocytosis. 
MMP activity is positively modulated by ions and reagents that 
induce MMP cleavage and activation. Zn2+chelators suppress 
MMP activity by depriving MMPs from the Zn2+critical for 
their activity. Cu2+ions may decrease MMP-2 secretion. MMPs 
are also inhibited by both endogenous and exogenous inhibi-
tors. Under normal physiological conditions, the proteolytic 
activity of the MMPs is controlled at any of the following three 
known stages: activation of the zymogens, transcription, and 
inhibition of the active forms by various TIMPs. In patholo-
gical conditions this equilibrium is shifted toward increased 
MMP activity leading to tissue degradation [14].
The role of MMPs in VV has been largely attributed to 
their proteolytic effects on ECM, degradation of the valve 
leaflets and weakening of vein wall structure. The localization 
of MMPs in the VV wall adventitia and fibroblasts is consistent 
with a role in ECM degradation [11].
The last two decades have made a great progress in under-
standing the role of MMPs in the development and progres-
sion of varicose veins. Although MMP effects are generally 
attributed to the degradation of extracellular matrix, their 
effects on the mechanisms of contraction / relaxation vein 
are unclear. In order to loose this enigma Joseph D. Raffetto 
and his team conducted a series of research.
The purpose of the first study was to test the hypothesis 
that prolonged increases in vein wall tension cause over-
expression of MMPs and decreased contractility promotes 
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venous dilation. The purpose of the second study was to 
test whether MMP-2 induced venous relaxation involves an 
endothelium-dependent mechanism, or an endothelium-in-
dependent inhibition of venous smooth muscle contraction. 
The task was to test this novel hypothesis, on evaluated effects 
of MMP-2 in inferior vena cava in the presence and absence 
of endothelium, in the presence and absence of inhibitors of 
endothelium-derived vasodilators, and during modulation of 
K+channel activity by depolarizing solutions and by activators 
and blockers of K+channels. Another study determined the 
mechanism which inhibits MMPs Ca+2 channels and gene-
rates venous dilation.
For this were used inferior vena cava obtained from rats 
of 12 weeks, weighing 250-300g, housed in the animal facility 
and fed standard rat chow and tap water in 12 hours / 12 h 
light / dark, then they were euthanized by CO2 inhalation. 
Inferior vena cava (IVC) were quickly excised, placed in Krebs 
solution, carefully dissected and cleaned of connective tissue 
under the microscope. IVC has been divided proportionally 
in four rings of 3 mm.
For the first experiment 4 vein segments were mounted 
on the wire hooks in different tissue baths at no specific or-
der to minimize the effects of variability in tissue size on the 
observed contractile response. Unless indicated otherwise, 
vein segments were stretched under 0.5g of basal tension and 
allowed to equilibrate for 1 hr in a temperature controlled, 
water-jacketed tissue bath, filled with 50 mL Krebs solution 
continuously bubbled with 95% O2, 5% CO2 at 37°C. The 
changes in isometric contraction were recorded on a Grass po-
lygraph. To determine the control contraction, IVC segments 
were stimulated twice with 96 mmol/L KCl solution. To test 
the IVC relaxation function, the tissues were stimulated with 
phenylephrine (Phe 10−5mol/L) to achieve a steady-state con-
traction, and then treated with acetylcholine (Ach, 1−5mol/L) 
to confirm the presence of intact endothelium. The veins 
were frozen to determine the expression and localization of 
MMPs using immunoblots and immunohistochemistry. These 
MMP-2 and -9 concentrations are physiologically consistent 
with the plasma and vein tissue levels in human which range 
between 1000 ng/g tissue (~1 mcg/ml) and 100 mcg/g tissue 
(~0.1 mcg/ml) [5].
In the second experiment there were measured the effects 
of MMP-2 on Phe- and KCl-induced contraction. To study 
the role of endothelium-derived vasodilators, the experiments 
were performed in the presence and absence of endothelium, 
L-nitro-arginine methyl ester (L-NAME), inhibitor of nitric 
oxide (NO) synthesis, indomethacin, inhibitor of prostacy-
clin (PGI2) synthesis, cromakalim, activator of ATP-sensitive 
K+channel (KATP); and iberiotoxin, blocker of large conduc-
tance Ca2+-dependent K+channel (BKCa) and smooth muscle 
hyperpolarization [3].
To evaluate the effects of MMP-2 on Ca2+ entry, IVC seg-
ments nontreated or pretreated with MMP-2 were incubated 
in Ca2+-free Krebs solution for 5 min, stimulated with Phe (10-
5M), then increasing extracellular CaCl2 concentrations ([Ca2+]
e) were added and the contractile response was measured after 
5 min in each [Ca2+]e. To further test the effect of MMP-2 
on Ca2+ entry, the effect of MMP-2 on Phe contraction was 
tested in IVC segments treated with the Ca2+ channel blocker 
diltiazem (10-5M) [7]. 
Later it was tested if the prolonged increases in vein wall 
tension affect venous contraction. Phe activates α-adrenergic 
receptors, and angiotensin II (AngII) activates angiotensin type 1 
receptors. It was found that the prolonged increases in basal tensi-
on are associated with reduction in Phe-induced IVC contraction, 
which may not be specific to α-adrenergic mediated responses 
as AngII-induced contraction was similarly reduced under these 
conditions. The observation that the reduced IVC contraction 
in tissues subjected to prolonged basal tension was reversed in 
tissues treated with TIMP-1, suggested possible involvement of 
MMP-2 and -9. The immunoblot analysis in IVC suggested in-
creased expression of MMP-2 and -9 during prolonged increases 
in basal tension. Also, immunohistochemical staining suggested 
localization of MMP-2 and -9 in the three layers of the vein wall. 
Additionally, prolonged increases in wall tension were associated 
with relative increases in MMP-2 and -9 in the vicinity of the 
smooth muscle layer, suggesting an effect on the contractile 
cells. Also, the observation that prolonged tension was associa-
ted with reduced contraction not only to Phe but also to AngII 
indicates that the reduction in contraction is not specific to a 
particular receptor. Furthermore, the Phe and AngII contraction 
were restored in veins treated with TIMP-1, suggesting that the 
reduction in contraction was not due to reduction in the Phe or 
AngII receptors, but rather it was due to increased MMP. It was 
also shown that MMP-2 causes significant inhibition of Phe- and 
AngII-induced IVC contraction likely through a post-receptor 
mechanism involving activation of plasmalemmal K+channels, 
membrane hyperpolarization, and inhibition of Ca2+influx. 
However, these studies do not exclude the possibility that the 
presence/activation of MMP-2 may lead to activation of other 
MMPs. MMP-2 and -9 have acute venodilatory effect in addi-
tion to their known effects on the extracellular matrix. MMP-2 
and MMP-9 induced inhibition of Phe contraction in vascular 
segments is dose-dependent. Further, it was demonstrated that 
the venodilator effects of MMP-2 and -9 are time-dependent. 
MMP-2 could cleave big endothelin-1 yielding a novel vasocon-
strictor and thereby enhance vascular contraction, an effect that 
will not be manifested in endothelium-denuded tissues. MMP-2 
induced venous relaxation could also be due to the enhanced 
release of nitric oxide (NO), prostacyclin (PGI2) or endothelium-
derived hyperpolarizing factor (EDHF). It was established that 
the NO synthesis (NOS) inhibitor L-NAME did not attenuate, 
and instead, enhanced MMP-2 induced IVC relaxation. MMP-2 
did not increase NO production. Although the data suggest that 
MMP-2 induced venous relaxation may not involve increased NO 
production, they do not rule out possible interaction between 
the NO pathway and MMP. NO, being a major vasodilator may 
downregulate the effects of MMP-2 on other endothelium-deri-
ved vasodilators, and NOS inhibition may unmask these effects. 
As well, the studies have shown that NO inhibition may increase 
MMP-9 expression in rat vascular smooth muscle cells. MMP-2 
may also directly or indirectly through increased endothelin-1 
production, induce NO synthesis (NOS) uncoupling and lead to 
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increased superoxide production and decreased NO bioactivity. 
It has also detected that the MMP-2 induced venous relaxation 
was not affected by the cyclooxygenase inhibitor indomethacin, 
suggesting that it does not involve increased PGI2synthesis and 
activation of PGI2-cAMP relaxation pathway. The inability of 
NOS and cyclooxygenase inhibition to block the MMP-2 indu-
ced venous relaxation raises the possibility of MMP-2 mediated 
release of EDHF leading to enhanced K+ efflux via K+ channels 
and venous smooth muscle hyperpolarization and relaxation. 
The high extracellular KCl creates a K+ concentration gradient 
that does not favor K+ efflux through plasma membrane K+ 
channels. MMP-2 did not inhibit venous contraction during 
membrane depolarization by high KCl, suggesting that MMP-2 
induced relaxation likely involves hyperpolarization and activa-
tion of a K+channel. K+ channels include the ATP-sensitive K+ 
channel (KATP), large conductance Ca2+-activated K+channel 
(BKCa), intermediate and small conductance Ca2+-activated 
K+ channel, voltage-gated K+ channels, and inward rectifier K+ 
channels. Activation of K+ channels likely causes smooth muscle 
hyperpolarization, and leads to decreased Ca2+influx through 
voltage-gated channels. MMP-2 can also activate directly the 
K+ channels. MMP may facilitate a conformational change in 
the BKCa channel from a closed state to an open state, during 
changes in voltage and intracellular Ca2+. As well the MMP-2 
may activate K+ channels through specific protease-activated 
receptors (PARs). PARs are activated by serine proteases such 
as thrombin, trypsin, and tryptase. The trypsin-induced PARs-
mediated relaxation was inhibited by KCl-precontraction, or 
pretreatment with apamin or charybdotoxin, blockers of small 
and intermediate Ca2+-activated K+channels, respectively. These 
facts suggest that PARs-mediated relaxation of the vasculature 
involves hyperpolarization of vascular smooth muscle and 
activation of Ca2+-activated K+ channels. In vascular smooth 
muscle, agonist-receptor interaction is coupled to increased rele-
ase of inositol-1,3,5-trisphosphate (IP3) and activation of plasma 
membrane Ca2+ channels. IP3 induces Ca2+ release from the 
intracellular Ca2+ stores. Parallel activation of Ca2+ channels 
promotes Ca2+ influx from the extracellular space. In Ca2+-free 
Krebs solution, Phe and AngII produced transient contraction, 
suggesting that they activate IP3-induced Ca2+ release. Diltiazem 
inhibited Phe-induced contraction, suggesting the presence of 
functional voltage-gated Ca2+ channels in IVC. Moreover, dil-
tiazem did not cause any further relaxation in MMP-2 treated 
IVC, indicating that the L-type channels are already inhibited by 
MMP-2. Importantly, MMP-2 caused further relaxation in diltia-
zem treated IVC, suggesting that during blockade of L-type Ca2+ 
channels, MMP-2 may inhibit other subclasses of voltage-gated 
channels (T- or N-type) or perhaps ligand-gated, store-operated 
Ca2+ channels or non-specific cation channels [3, 5, 7].
Conclusions
While inherent differences in the physiologic behavior 
and structure of rat veins and human veins make it difficult 
to extrapolate the response of rat IVC to human veins, the 
results indicate that the magnitude and duration of vein 
wall tension have significant impact on venous function 
and MMP expression. It was established that increases in 
basal tension cause a significant and irreversible reduction 
in IVC contraction, suggesting structural changes and irre-
versible vein damage. Increases in magnitude and duration 
of wall tension are associated with reduced contraction and 
overexpression of MMP-2 and -9. MMP-2 causes relaxa-
tion of Phe contraction in IVC segments by a mechanism 
involving hyperpolarization and activation of BKCa. Large 
amounts of MMP-2 have been detected in the plasma and 
venous tissues of patients with varicose veins. In addition, it 
is possible that some of the effects of MMP-2 can be due to 
activation of other endogenous MMPs. However, MMP-1, 
-3, -9, and -13 are also expressed in human varicose veins. 
The obtained results are the first step in the establishment 
of a new phlebology development direction. Understanding 
the molecular basis of VVs formation and MMPs-induced 
changes in endothelial cells (Ecs) and vascular smooth 
muscle (VSM) function and vein wall remodeling will 
provide valuable information on the mechanisms involved 
in CVD development and progression. Using human veins, 
obtained by minimal surgical manipulation can reveal not 
only the effects of MMPs on the veins, but can also divert 
treatment for use of MMPs inhibitor in the treatment of va-
ricose veins. Previous attempts to study the effects of MMP 
inhibitors, such as doxycycline, batimostat and marimostat 
have been carried out, but they have significant side effects, 
especially on the musculoskeletal system. A deeper study 
of MMPs and their effects can lead to the creation of new 
synthetic inhibitors and their potential use. In the context 
of accelerated technological progress all they may become 
phlebology targets tomorrow.
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